dexmedetomidine has been researched along with oxidopamine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Han, X; Li, Y; Xing, Q; Zhang, P; Zhao, L | 1 |
| Haghdoost-Yazdi, H; Minaei, A | 1 |
2 other study(ies) available for dexmedetomidine and oxidopamine
| Article | Year |
|---|---|
Dexmedetomidine Regulates 6-hydroxydopamine-Induced Microglial Polarization.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Cell Line; Cell Polarity; Cell Survival; Dexmedetomidine; Dose-Response Relationship, Drug; Inflammation Mediators; Mice; Microglia; Oxidopamine | 2017 |
Dexmedetomidine attenuates the induction and reverses the progress of 6-hydroxydopamine- induced parkinsonism; involvement of K
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Anti-Inflammatory Agents; Dexmedetomidine; Disease Progression; Inflammation Mediators; KATP Channels; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Receptors, Adrenergic, alpha-2 | 2019 |